[go: up one dir, main page]

PL2994125T3 - Nintedanib do zastosowania w leczeniu nsclc - Google Patents

Nintedanib do zastosowania w leczeniu nsclc

Info

Publication number
PL2994125T3
PL2994125T3 PL14721905T PL14721905T PL2994125T3 PL 2994125 T3 PL2994125 T3 PL 2994125T3 PL 14721905 T PL14721905 T PL 14721905T PL 14721905 T PL14721905 T PL 14721905T PL 2994125 T3 PL2994125 T3 PL 2994125T3
Authority
PL
Poland
Prior art keywords
nintedanib
nsclc
behandlung von
der behandlung
zur anwendung
Prior art date
Application number
PL14721905T
Other languages
English (en)
Inventor
Birgit GASCHLER-MARKEFSKI
Rolf Kaiser
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48236813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2994125(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PL2994125T3 publication Critical patent/PL2994125T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL14721905T 2013-05-10 2014-05-08 Nintedanib do zastosowania w leczeniu nsclc PL2994125T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13167358 2013-05-10
PCT/EP2014/059456 WO2014180955A1 (en) 2013-05-10 2014-05-08 Efficacious treatment of nsclc and predictive clinical marker of the responsiveness of a tumour to a treatment
EP14721905.9A EP2994125B1 (en) 2013-05-10 2014-05-08 Nintedanib zur anwendung in der behandlung von nsclc

Publications (1)

Publication Number Publication Date
PL2994125T3 true PL2994125T3 (pl) 2019-05-31

Family

ID=48236813

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14721905T PL2994125T3 (pl) 2013-05-10 2014-05-08 Nintedanib do zastosowania w leczeniu nsclc

Country Status (19)

Country Link
US (2) US20140350022A1 (pl)
EP (1) EP2994125B1 (pl)
JP (1) JP2016518396A (pl)
KR (1) KR20160006226A (pl)
CN (1) CN105188698A (pl)
AU (1) AU2014264533B2 (pl)
BR (1) BR112015027218A8 (pl)
CA (1) CA2911867A1 (pl)
CL (1) CL2015003267A1 (pl)
DK (1) DK2994125T3 (pl)
EA (1) EA034520B1 (pl)
ES (1) ES2693773T3 (pl)
HU (1) HUE040240T2 (pl)
MX (1) MX364523B (pl)
PH (1) PH12015502516A1 (pl)
PL (1) PL2994125T3 (pl)
TR (1) TR201815464T4 (pl)
TW (1) TW201536290A (pl)
WO (1) WO2014180955A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
US20190002988A1 (en) * 2015-12-08 2019-01-03 Boehringer Ingelheim International Gmbh Method of using a ret fusion gene as a biomarker to select non small cell lung cancer (nsclc) and thyroid cancer patients for a cancer treatment
JP2020512364A (ja) * 2017-03-28 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 筋ジストロフィーの処置方法において使用するためのニンテダニブ

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1870400A1 (en) 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
RU2525114C2 (ru) 2007-12-03 2014-08-10 Бёрингер Ингельхайм Интернациональ Гмбх Способ получения производного индолинона
PE20091445A1 (es) 2007-12-03 2009-10-19 Boehringer Ingelheim Int Derivados de indolinona y procedimiento para su fabricacion
UA107560C2 (uk) 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
NO2299987T3 (pl) 2008-06-06 2018-07-21
EP2985025B1 (en) * 2008-06-06 2018-01-17 Boehringer Ingelheim International Gmbh Pharmaceutical combination
US8802384B2 (en) 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment

Also Published As

Publication number Publication date
KR20160006226A (ko) 2016-01-18
CA2911867A1 (en) 2014-11-13
EA034520B1 (ru) 2020-02-17
EP2994125B1 (en) 2018-08-01
BR112015027218A2 (pt) 2017-07-25
MX2015015525A (es) 2016-02-05
HUE040240T2 (hu) 2019-03-28
WO2014180955A1 (en) 2014-11-13
MX364523B (es) 2019-04-30
JP2016518396A (ja) 2016-06-23
US20160143906A1 (en) 2016-05-26
TR201815464T4 (tr) 2018-11-21
BR112015027218A8 (pt) 2018-01-30
TW201536290A (zh) 2015-10-01
EA201501095A1 (ru) 2016-05-31
AU2014264533B2 (en) 2019-07-18
CN105188698A (zh) 2015-12-23
US20140350022A1 (en) 2014-11-27
CL2015003267A1 (es) 2016-07-15
EP2994125A1 (en) 2016-03-16
AU2014264533A1 (en) 2015-10-29
DK2994125T3 (en) 2018-11-05
ES2693773T3 (es) 2018-12-13
PH12015502516A1 (en) 2016-02-29

Similar Documents

Publication Publication Date Title
IL273205A (en) Preparations and methods
GB2533892B (en) Compositions and methods
PL3214956T3 (pl) Roztwór zawierający nikotynę w postaci nieprotonowanej i protonowanej
GB201308072D0 (en) Compositions and methods
GB201306633D0 (en) Biaising circuitry and method thereof
GB201301626D0 (en) Composition comprising 15-OHEPA and methods of using the same
GB201401066D0 (en) Improvements in and relating to screens
GB201305414D0 (en) Method and composition
ZA201506674B (en) Ship1 modulators and methods related thereto
IL241168A0 (en) 1 ship modulators and related methods
GB201305813D0 (en) Compositions and methods
ZA201504477B (en) Ship1 modulators and methods related thereto
GB201307989D0 (en) Novel combinations and use
HUE040240T2 (hu) Nintedanib NSCLC kezelésére történõ alkalmazásra
GB2517846B (en) Improvements in and relating to loudspeakers
GB201308753D0 (en) Compounds and their use in therapy
GB201513464D0 (en) Improvements in and relating to road guarding lamps
GB201415361D0 (en) Hosiery and method
SG11201509202UA (en) Filtration device and filtration method using same
GB2516902B (en) Modulation unit and modulation method
GB201319273D0 (en) Improvements in structural members and methods relating thereto
GB201308217D0 (en) Compounds and their use in therapy
GB2530075B (en) Improvements in and relating to eyewashing
GB201412354D0 (en) Improvements in and relating to loudspeakers
GB201408062D0 (en) Improvements in and relating to loudspeakers